$120.00
In stock
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 | — | $120.00 |
| 6 | 66.67 % | $40.00 |
| 12 | 68.33 % | $38.00 |
| 20+ | 70.83 % | $35.00 |
Free bacteriostatic water with every order.
Use our Research Peptide Storage Guide — Laboratory Use Only — to ensure proper handling and stability for controlled experimental applications. Not for human consumption, therapeutic, or diagnostic use.
Chemical Formula: C₉₆H₁₅₃N₂₉O₂₃ (peptide fragment–based structure)
Molecular Weight: ~2,109 g/mol
CAS Number: 221231-10-3
Structure: Modified C-terminal fragment of human growth hormone (amino acids 176–191) engineered to retain lipolytic activity without full GH receptor activation
Form: Lyophilized peptide powder
Solubility: Soluble in sterile water or buffered aqueous solution
Stability: Stable when frozen; limited stability after reconstitution
Half-Life: Short systemic half-life with localized metabolic activity
Storage: Store refrigerated at 36–46°F (2–8°C); protect from light and moisture
Derived from the lipolytic region of human growth hormone to promote fat breakdown
Stimulates adipose tissue fat mobilization without significantly impacting blood glucose or IGF-1 levels in research models
Targets fat reduction pathways while minimizing broader growth hormone–like systemic effects
Enhances fatty acid utilization as an energy substrate in metabolic studies
Studied for reductions in adipose tissue accumulation in preclinical and clinical models
Investigated for improved lean-to-fat mass ratio in metabolic research
Explored for enhanced fat oxidation and improved lipid metabolism markers
Evaluated for lipolytic effects without significantly altering endogenous growth hormone levels
Clinical and preclinical research indicates:
Reduced visceral fat accumulation
Decreased body weight in obesity models
Improved lean-to-fat mass ratio
Studies demonstrate:
Increased lipolytic activity in adipose tissue
Improved lipid metabolism markers
Enhanced fat oxidation during metabolic stress
Evidence suggests:
Minimal impact on blood glucose regulation
No strong stimulation of IGF-1 compared to full growth hormone
Neutral effect on systemic insulin signaling at stud
Research indicates:
Favorable tolerability in clinical trials
Minimal impact on growth plate activity
Limited systemic endocrine disruption compared to GH therapy
Observed effects appear dose-dependent and typically transient.
Mild injection site irritation
Temporary changes in appetite or energy
Dosing is generally individualized and may require gradual titration
Independent laboratory testing confirms purity and composition
Purity
Batch
Date
